Yuhan sold technology YH1885 to SB at a hundred million dollar.

Yuhan has developed a new anti-peptic ulcer agent, YH1885 ( a proton-pump channel inhibitor) as one of the government's G7 projects and sold it out to Smithkline Beecham at U$100 million of its royalty. Two parties made an agreement on Oct. 2 at the Ministry of Science and Technology at a lump-sum fee of U$100 million payable during the research period and 10% revolving royalty until 2016 after...